Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
RATIONALE: Romidepsin and erlotinib hydrochloride may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I/II trial is studying the side effects and best dose of romidepsin when
given together with erlotinib hydrochloride and to see how well they work in treating
patients with stage III or stage IV non-small cell lung cancer.